{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":40},"studies":[{"active":true,"description":"A Phase IIIb, randomized, multicenter, open-label trial of&#160;Atezolizumab plus Bevacizumab<br />versus transarterial Chemoembolization (TACE)&#160;in intermediate-stage HepatoCellular Carcinoma","eudractNumber":"2020-004210-35","id":6680,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT04803994","phase":{"id":"ph_10","name":"Phase IIIB"},"recruitmentStart":"2022-04-05T10:12:06+02:00","shortTitle":"ABC-HCC","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Beobachtungsstudie und Biobank f&#252;r Rezidive einer akuten lymphoblastischen Leuk&#228;mie im Kindes- und Jugendalter<br />","eudractNumber":null,"id":656,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2012-10-01T09:06:33+02:00","shortTitle":"ALL- REZ BFM","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator&#8217;s Choice in Participants with Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer</div>","eudractNumber":"2025-520555-89","id":11331,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":"NCT07213674","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-15T10:26:05+01:00","shortTitle":"AMG 509 20230239","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter \nStudy of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell \nLung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent \nChemoradiation Therapy","eudractNumber":"2023-506235-15","id":9281,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06117774","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-13T10:24:08+01:00","shortTitle":"AMG 757 20230016 (DeLLphi-306)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","eudractNumber":"2024-511838-12-00","id":9817,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06598306","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2024-11-26T10:56:41+01:00","shortTitle":"AMG 757 20230298 (DeLLphi-308)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3, Open-label, Multicenter, Randomized&#160;Study of Xaluritamig vs Cabazitaxel or Second&#160;Androgen Receptor-Directed Therapy in&#160;Subjects With Metastatic Castration-Resistant&#160;Prostate Cancer Previously Treated With&#160;Chemotherapy","eudractNumber":"2024-513968-25","id":10039,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-25T09:31:19+02:00","shortTitle":"AMG509 20230005 STEAP-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123&#160;Consisting of Genetically Modified T cells Carrying Reverse Chimeric&#160;Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123&#160;Target Module (R-TM123) for the Treatment of Patients With Selected&#160;Hematologic Malignancies Positive for CD123","eudractNumber":"2022-501797-19","id":8333,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD123 ","id":"mt_79"}],"nctNumber":"NCT05949125","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2024-02-20T12:54:04+01:00","shortTitle":"AVC-201-01","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 2/3 Open Label Randomized Study of\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713","eudractNumber":"2025-521124-29-00","id":11332,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT07155187","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2026-03-02T10:56:01+01:00","shortTitle":"Abbvie M25-713 AndroMETa-Lung-713","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Allogene Stammzelltransplantation im Vergleich zur konventionellen \nTherapie als Salvage-Therapie f&#252;r Patienten mit rezidiviertem / \nprogredientem multiplen Myelom nach einer Erstlinientherapie\n(AlloRelapseMMStudy)","eudractNumber":"2021-001005-67","id":8119,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05675319","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-04-05T10:24:45+02:00","shortTitle":"AlloRelapseMMStudy - CTC201637","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/ Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma and t(11; 14)","eudractNumber":"2021-003614-39","id":9079,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT04973605","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2025-05-07T12:24:50+02:00","shortTitle":"BGB-11417-105","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]}]},"initialUrl":"/api/studies?lang=de&page=0&size=10&tls=tl_2","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase IIIb, randomized, multicenter, open-label trial of&#160;Atezolizumab plus Bevacizumab<br />versus transarterial Chemoembolization (TACE)&#160;in intermediate-stage HepatoCellular Carcinoma\",\"name\":\"ABC-HCC\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6680\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Beobachtungsstudie und Biobank f&#252;r Rezidive einer akuten lymphoblastischen Leuk&#228;mie im Kindes- und Jugendalter<br />\",\"name\":\"ALL- REZ BFM\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/656\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<div>A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator&#8217;s Choice in Participants with Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer</div>\",\"name\":\"AMG 509 20230239\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11331\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter \\nStudy of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell \\nLung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent \\nChemoradiation Therapy\",\"name\":\"AMG 757 20230016 (DeLLphi-306)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9281\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)\",\"name\":\"AMG 757 20230298 (DeLLphi-308)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9817\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3, Open-label, Multicenter, Randomized&#160;Study of Xaluritamig vs Cabazitaxel or Second&#160;Androgen Receptor-Directed Therapy in&#160;Subjects With Metastatic Castration-Resistant&#160;Prostate Cancer Previously Treated With&#160;Chemotherapy\",\"name\":\"AMG509 20230005 STEAP-1\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10039\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123&#160;Consisting of Genetically Modified T cells Carrying Reverse Chimeric&#160;Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123&#160;Target Module (R-TM123) for the Treatment of Patients With Selected&#160;Hematologic Malignancies Positive for CD123\",\"name\":\"AVC-201-01\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8333\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 2/3 Open Label Randomized Study of\\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713\",\"name\":\"Abbvie M25-713 AndroMETa-Lung-713\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11332\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Allogene Stammzelltransplantation im Vergleich zur konventionellen \\nTherapie als Salvage-Therapie f&#252;r Patienten mit rezidiviertem / \\nprogredientem multiplen Myelom nach einer Erstlinientherapie\\n(AlloRelapseMMStudy)\",\"name\":\"AlloRelapseMMStudy - CTC201637\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8119\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/ Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma and t(11; 14)\",\"name\":\"BGB-11417-105\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9079\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=1&tls=tl_2\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}